Learn about XTIDE

Sybrava

What is XTIDE?

XTIDE is a medication used to treat metastatic castration-resistant prostate cancer (mCRPC). It helps control cancer that continues to grow even when testosterone levels are low due to androgen deprivation therapy (ADT) or surgical castration.

When is XTIDE Prescribed?

For adult men with mCRPC who are asymptomatic or only mildly symptomatic after failing ADT and who are not yet candidates for chemotherapy.
For adults with mCRPC whose cancer has progressed after chemotherapy with docetaxel.
The recommended dose is 160 mg of enzalutamide, taken as a single oral dose once daily. The actual may be customised basis your requirement by your treating doctor

Important Notes:

- Patients who are not surgically castrated should continue their medical castration using LHRH analogs while on treatment.
- Always follow your healthcare provider's instructions for dosing and treatment.
- If you have any questions or concerns, please talk to your healthcare provider!